Rosa Catarino

Rosa Catarino

Auto-generated profile, based on publicly available information

Rosa Catarino

Gynecology Division, Geneva University Hospitals, Geneva, Switzerland

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2015 in World Journal of Clinical Oncology
Verified
Journal Article
Open access
RCRosa Catarino
Rosa Catarino
PPPatrick Petignat
Patrick Petignat
GDGabriel Dongui
Gabriel Dongui
PVPierre Vassilakos
Pierre Vassilakos
Cervical cancer (CC) represents the fourth most common malignancy affecting women all over the world and is the second most common in developing areas. In these areas, the burden from disease remains important because of the difficulty in implementing cytology-based screening programmes. The main obstacles inherent to these countries are poverty and a lack of healthcare infrastructures and trained practitioners. With the availability of new technologies, researchers have attempted to find new strategies that are adapted to low- and middle-income countries (LMIC) to promote early diagnosis of cervical pathology. Current evidence suggests that human papillomavirus (HPV) testing is more effective than cytology for CC screening. Therefore, highly sensitive tests have now been developed for primary screening. Rapid molecular methods for detecting HPV DNA have only recently been commercially available. This constitutes a milestone in CC screening in low-resource settings because it may help overcome the great majority of obstacles inherent to previous screening programmes. Despite several advantages, HPV-based screening has a low positive predictive value for CC, so that HPV-positive women need to be triaged with further testing to determine optimal management. Visual inspection tests, cytology and novel biomarkers are some options. In this review, we provide an overview of current and emerging screening approaches for CC. In particular, we discuss the challenge of implementing an efficient cervical screening adapted to LMIC and the opportunity to introduce primary HPV-based screening with the availability of point-of-care (POC) HPV testing. The most adapted screening strategy to LMIC is still a work in progress, but we have reasons to believe that POC HPV testing makes part of the future strategies in association with a triage test that still needs to be defined.

18 April 2013 in Sleep and Breathing
Verified
Journal Article
Closed access
PDF file
RCRosa Catarino
Rosa Catarino
JSJorge Spratley
Jorge Spratley
ICIsabel Catarino
Isabel Catarino
Nuno LunetNuno Lunet
Nuno Lunet
MPManuel Pais-Clemente
Manuel Pais-Clemente

24 November 2014 in International Journal of Cancer
Verified
Journal Article
Open access
PDF file
JBJérôme Bigoni
Jérôme Bigoni
MGMélissa Gundar
Mélissa Gundar
PTPierre‐Marie Tebeu
Pierre‐Marie Tebeu
ABAdamo Bongoe
Adamo Bongoe
SSSonja Schäfer
Sonja Schäfer
PPPatrick Petignat
Patrick Petignat
Developing countries are interested in using human papillomavirus (HPV) testing as a primary screening test for cervical cancer prevention programs. The low specificity of the HPV assay requires triage testing of HPV‐positive women. The aim of the study is to compare visual inspection with acetic acid (VIA) and cytology as triage testing methods in HPV‐positive women to detect cervical intraepithelial neoplasia or Grade 2 or higher (CIN2+). The study was conducted in two Cameroonian towns (Yaoundé and Edea) and included 846 eligible women aged 25 to 65 years. All participants performed self‐HPV testing. HPV‐positive women (n = 259) were randomly assigned to be tested either by VIA (VIA group) or cytology (cytology group). HPV‐positive women had both cervical biopsy and endocervical curettage to detect biopsy‐confirmed CIN2+. All statistical tests were two‐sided. The prevalence of HPV was 38.5%, and the mean age of HPV‐positive women was 41.5 ± 10.1 years. One hundred ninety‐eight women (97 in the VIA group and 99 in the cytology) were randomly assigned to one of the two testing arms. The sensitivity of VIA was 25.0% (95% CI, 7.1–59.1%), and the sensitivity of cytology was 90.0% (59.6–98.2%). The specificity was 74.2% (95% CI, 64.2–82.1%) for VIA and 85.2% (76.3–91.2%) for cytology. ROC area for cytology was 0.910 against the 0.496 area for VIA. In this trial, VIA was inferior to cytology as a triage test among HPV‐positive women. Further investigations are needed to determine the optimal triage method for HPV‐positive women.

4 June 2017 in Cancer Medicine
Verified
Journal Article
Open access
PDF file
MKMargot Kunckler
Margot Kunckler
FSFanny Schumacher
Fanny Schumacher
BKBruno Kenfack
Bruno Kenfack
RCRosa Catarino
Rosa Catarino
MVManuela Viviano
Manuela Viviano
PPPatrick Petignat
Patrick Petignat
Cervical cancer (CC) is the leading cause of cancer‐related death among women in sub‐Saharan Africa, primarily because of limited access to effective screening and preventive treatment. Our aim was to assess the feasibility of a human papillomavirus (HPV)‐based CC screen‐and‐treat approach in a low‐resource context. We recruited 1012 women aged 30–49 years through a CC screening campaign conducted in the District Hospital of Dschang, Cameroon. Participants performed HPV self‐sampling, which was tested for high‐risk HPV (HR‐HPV) DNA using the point‐of‐care Xpert HPV assay. All HPV‐positive women were invited for visual inspection with acetic acid and Lugol's iodine (VIA/VILI) to exclude CC or enable triage. A cervical sample for histological analysis was also collected. Women positive for HPV 16/18/45 and for other HR‐HPV with pathological VIA/VILI were selected to undergo treatment with thermocoagulation. The HPV prevalence in the study population was 18.5% (n = 187); of these cases, 20 (10.6%), 42 (22.3%) and 140 (74.9%) were positive for HPV16, HPV18/45 and other HR‐HPV types, respectively. Overall, 107/185 (57.8%) VIA/VILI examinations were classified as pathological and 78 (42.2%) as normal. Women positive for HPV16/18/45 were 4.2 times more likely to harbor cervical intraepithelial neoplasia grade 2 or worse (CIN2+) than those with other HPV types. The specificity of HPV 16/18/45 genotypes for detection of high‐grade lesions among HR‐HPV positive women was higher than that of VIA/VILI in all age groups. The sensitivity and specificity of VIA/VILI in detecting CIN2+ among HPV positive women were 80% and 44%, respectively. Overall, 110/121 screen‐positive women (90.9%) were eligible for, and were treated with, thermocoagulation. An HPV‐based screen‐and‐treat approach is feasible in a low‐resource context and may contribute to improving the effectiveness of CC prevention programs. Immediate thermocoagulation treatment for women who are HPV16‐ and/or HPV18/45‐positive is a practical approach for the treatment of CIN2+. The combination of HPV‐testing and VIA/VILI for CC screening might reduce overtreatment.

26 July 2017 in BJOG: An International Journal of Obstetrics & Gynaecology
Verified
Journal Article
Closed access
PDF file
RCRosa Catarino
Rosa Catarino
SSSonja Schäfer
Sonja Schäfer
PVPierre Vassilakos
Pierre Vassilakos
PPPatrick Petignat
Patrick Petignat
MAMarc Arbyn
Marc Arbyn

1 June 2017 in International Journal of Women's Health
Verified
Journal Article
Open access
PDF file
CGCaroline Gallay
Caroline Gallay
AGAnne Girardet
Anne Girardet
MVManuela Viviano
Manuela Viviano
RCRosa Catarino
Rosa Catarino
ABAnne-Caroline Benski
Anne-Caroline Benski
PPPatrick Petignat
Patrick Petignat
Background: Visual inspection after application of acetic acid (VIA) and Lugol’s iodine (VILI) is a cervical cancer (CC) screening approach that has recently been adopted in low- and middle-income countries (LMIC). Innovative technologies allow the acquisition of consecutive cervical images of VIA and VILI using a smartphone application. The aim of this study was to evaluate the quality of smartphone images in order to assess the feasibility and usability of a mobile application for CC screening in LMIC. Methods: Between May and November 2015, women aged 30–65 years were recruited in a CC screening campaign in Madagascar. Human papillomavirus-positive women were invited to undergo VIA/VILI assessment. Pictures of their cervix were taken using a Samsung Galaxy S5 with an application called “Exam”, which was designed to obtain high-quality images and to classify them in the following sequence: native, VIA, VILI and posttreatment. Experts in colposcopy were asked to evaluate if the quality of the pictures was sufficient to establish the diagnosis and to assess sharpness, focus and zoom. Results: The application use was simple and intuitive, and 208 pictures were automatically classified and recorded in the patient’s file. The quality was judged as adequate for diagnosis in 93.3% of cases. The interobserver agreement was κ =0.45 (0.23–0.58), corresponding to a moderate agreement on the common scale of kappa values. Conclusion: This smartphone application allows the acquisition of good quality images for VIA/VILI diagnosis. The classification of images in a patient database makes them accessible to on- and off-site experts, and allows continuous clinical education. Smartphone applications may offer an alternative to colposcopy for CC screening in LMIC.